Genmab/$GMAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Ticker
- $GMAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab Metrics
BasicAdvanced
$21B
2.73
$12.65
0.69
-
Price and volume
Market cap
$21B
Beta
0.69
52-week high
$35.43
52-week low
$23.62
Average daily volume
2.6M
Financial strength
Current ratio
2.457
Quick ratio
2.441
Long term debt to equity
0.833
Total debt to equity
0.885
Interest coverage (TTM)
4.96%
Profitability
EBITDA (TTM)
1,377
Gross margin (TTM)
93.03%
Net profit margin (TTM)
19.08%
Operating margin (TTM)
32.29%
Effective tax rate (TTM)
13.02%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
8.79%
Return on equity (TTM)
14.00%
Valuation
Price to earnings (TTM)
2.73
Price to revenue (TTM)
0.515
Price to book
22.49
Price to tangible book (TTM)
-40.97
Price to free cash flow (TTM)
2.451
Free cash flow yield (TTM)
40.80%
Free cash flow per share (TTM)
14.091
Growth
Revenue change (TTM)
22.26%
Earnings per share change (TTM)
-36.79%
3-year revenue growth (CAGR)
18.55%
10-year revenue growth (CAGR)
34.68%
3-year earnings per share growth (CAGR)
5.57%
10-year earnings per share growth (CAGR)
22.19%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Analyst projections of the future price of Genmab stock.
Bulls say / Bears say
First-half revenue rose 25% to $2.05 billion, prompting Genmab to raise its 2026 revenue guidance to $4.325–$4.525 billion. The upgrade was driven by stronger DARZALEX royalties and EPKINLY sales, showing solid current trading momentum. (Genmab)
EPKINLY/TEPKINLY sales grew 48% year on year to $312 million in the first half, and a Phase 3 trial showed a statistically significant improvement in progression-free survival. European approval in follicular lymphoma adds another route for the drug to expand beyond its existing market. (Genmab, Genmab)
Genmab expects major Phase 3 readouts for epcoritamab, Rina-S and petosemtamab in the fourth quarter of 2026, creating several near-term catalysts. Petosemtamab also has FDA Fast Track and Breakthrough Therapy designations in head and neck cancer. (Stock Analysis, Genmab)
The 2026 revenue midpoint includes $3.687 billion of royalties out of $4.425 billion total, leaving the forecast heavily reliant on royalty income. DARZALEX is the largest contributor, so weaker sales or an adverse development at its partner would have an outsized effect on Genmab. (Genmab)
Genmab financed the Merus acquisition with $5.5 billion of borrowings, while first-half integration charges reached $77 million. The enlarged debt load and integration burden reduce financial flexibility just as the company is increasing investment in its pipeline and commercial infrastructure. (Genmab, Genmab)
Epcoritamab’s EPCORE DLBCL-1 study did not meet its US overall-survival primary endpoint, leaving uncertainty over conversion of its accelerated approval. The company also faces strong competition in bispecific antibodies, so further clinical or regulatory setbacks could weaken a key growth driver. (Insider Monkey, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Genmab News
AllArticlesVideos
Genmab A/S Q2 Earnings Call Highlights
MarketBeat1 month ago
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Business Wire2 months ago
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Benzinga3 months ago
Funds containing Genmab
AllUSDGBP
Fund name | Fund size | $GMAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.18% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.